Price$24.83+0.26 (+1.06%)
02:00 PM07:45 PM
News · 26 weeks91-75%
2025-10-262026-04-19
Mix2590d
- Insider10(40%)
- SEC Filings5(20%)
- Other5(20%)
- Analyst2(8%)
- Earnings2(8%)
- Leadership1(4%)
Latest news
25 items- ANALYSTSTAAR Surgical upgraded by Canaccord Genuity with a new price targetCanaccord Genuity upgraded STAAR Surgical from Hold to Buy and set a new price target of $27.00
- SECSTAAR Surgical Company filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - STAAR SURGICAL CO (0000718937) (Filer)
- PRSTAAR Surgical Announces Preliminary Net Sales for First Quarter 2026STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced preliminary net sales for the first quarter ended April 3, 2026. STAAR is announcing its preliminary net sales in advance of its quarterly earnings announcement because it expects to be interacting with members of the investment community, as well as with surgeons and other members of the ophthalmology community, at the ASCRS Annual Meeting in Washington, D.C. Net sales for the first quarter of 2026 are expected to be in excess of $90 million, compared to net sales of $42.6 million for the first quarter of 2025. "We
- SECAmendment: SEC Form SCHEDULE 13G/A filed by STAAR Surgical CompanySCHEDULE 13G/A - STAAR SURGICAL CO (0000718937) (Subject)
- INSIDERInterim Co-CEO and Pres. & COO Foust Warren converted options into 37,500 shares, increasing direct ownership by 144% to 63,588 units (SEC Form 4)4 - STAAR SURGICAL CO (0000718937) (Issuer)
- INSIDERSEC Form 4 filed by Interim Co-CEO and CFO Andrews Deborah J4 - STAAR SURGICAL CO (0000718937) (Issuer)
- INSIDERChief Development Officer Michna Magda converted options into 23,773 shares and covered exercise/tax liability with 8,529 shares, increasing direct ownership by 105% to 29,668 units (SEC Form 4)4 - STAAR SURGICAL CO (0000718937) (Issuer)
- INSIDERDirector Broadwood Partners, L.P. bought $12,266,545 worth of shares (670,213 units at $18.30) (SEC Form 4)4 - STAAR SURGICAL CO (0000718937) (Issuer)
- INSIDERSEC Form 4 filed by STAAR Surgical Company4 - STAAR SURGICAL CO (0000718937) (Issuer)
- INSIDERSEC Form 4 filed by Director Lebuhn Richard T.4 - STAAR SURGICAL CO (0000718937) (Issuer)
- INSIDERSEC Form 4 filed by STAAR Surgical Company4 - STAAR SURGICAL CO (0000718937) (Issuer)
- SECSTAAR Surgical Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - STAAR SURGICAL CO (0000718937) (Filer)
- PRSTAAR Surgical Issues Shareholder LetterSTAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued a Shareholder Letter on Tuesday, March 3 after the market close. STAAR's results release can be found here: https://investors.staar.com/news-and-events/press-releases. Fellow Shareholders, This past month marked an important transition for our company as we stepped into the roles of Interim co-Chief Executive Officers. We are honored by the Board's confidence and deeply grateful for the dedication of our employees, the loyalty of our customers, and the opportunity to serve you—our shareholders. It is with great pleasure
- PRSTAAR Surgical Reports Fourth Quarter and Fiscal Year 2025 ResultsConfident in China Progress and Future Roadmap A Clear Path Toward Sustainable Profitability and Growth Board and Leadership Transitions Support Strategy Execution and Shareholder Value Creation STAAR Interim co-CEOs Issue Letter to Shareholders Earnings Call and Webcast Today at 5:30 PM Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the fourth quarter and fiscal year ended January 2, 2026. STAAR's Interim co-CEOs will be issuing a Letter to Shareholders after this earnings release, which can be found here: https://investors.staar.com/new
- SECSEC Form 10-K filed by STAAR Surgical Company10-K - STAAR SURGICAL CO (0000718937) (Filer)
- PRSTAAR Surgical Surpasses 4 Million ICLs Sold Globally, Reflecting Ongoing Shift Away from Laser-Based Vision CorrectionSTAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that more than 4 million Implantable Collamer® Lenses (ICLs) have been sold worldwide, marking a milestone in the global shift away from laser-based refractive surgery. This achievement underscores the growing global preference for lens-based solutions in refractive vision correction as patients and surgeons increasingly choose alternatives to traditional laser-based procedures, which require corneal tissue removal. "Surpassing 4 million ICLs sold is a major milestone for STAAR," said Deborah Andrews, Interim Co-Chie
- PRSTAAR Surgical to Host Fourth Quarter and Fiscal Year 2025 Earnings Conference Call and Webcast on March 3, 2026STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the fourth quarter and fiscal year ended January 2, 2026, on Tuesday, March 3 after the market close. The Company will also host an earnings call and webcast at 5:30 p.m. ET to discuss its financial results and business progress. Event: STAAR Surgical Fourth Quarter and Fiscal Year 2025 Financial Results Webcast Date: Tuesday, March 3, 2026 Time: 5:30 p.m. ET/ 2:30 p.m. PT Location: https://event.choruscall.com/mediaframe/webcast.html?webcastid=J3bNAuVd Topics on the c
- PRFDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision CorrectionNew FDA expansion of U.S. age indication extends EVO ICL use for patients 21 to 60 years old – making EVO ICL available to nearly 8 million additional refractive patients Lens-based vision correction with EVO ICL is now the leading procedure for U.S. patients with -8.0 diopters and above U.S. refractive market continues to shift away from laser-based refractive procedures that require corneal tissue removal STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded age indication for EVO/EVO+ Visian®
- INSIDERNew insider Wang Christopher Min Fang claimed ownership of 3,257,130 shares (SEC Form 3)3 - STAAR SURGICAL CO (0000718937) (Issuer)
- SECSTAAR Surgical Company filed SEC Form 8-K: Leadership Update8-K - STAAR SURGICAL CO (0000718937) (Filer)
- INSIDERSEC Form 4 filed by Interim Co-CEO and Pres. & COO Foust Warren4 - STAAR SURGICAL CO (0000718937) (Issuer)
- INSIDERSEC Form 4 filed by Interim Co-CEO and CFO Andrews Deborah J4 - STAAR SURGICAL CO (0000718937) (Issuer)
- ANALYSTWedbush initiated coverage on STAAR Surgical with a new price targetWedbush initiated coverage of STAAR Surgical with a rating of Neutral and set a new price target of $26.00
- SECSTAAR Surgical Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - STAAR SURGICAL CO (0000718937) (Filer)
- PRSTAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOsSearch Committee Has Initiated a Global Search to Select Next CEO STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors (the "Board") has appointed Warren Foust, President and Chief Operating Officer, and Deborah Andrews, Chief Financial Officer, as interim co-Chief Executive Officers, effective February 1, 2026. Mr. Foust and Ms. Andrews will work together with the other members of the executive leadership team, with support and guidance from the Board, as they lead the Company and manage its day-to-day operations.